Patients & Caregivers
Contact Us
Français
Home
Overview
Major Accomplishments
Working at Merck
Search Jobs, Submit Resume, Log on
Career Choices
Students and recent Grads
Careers Questions
Partners
Company Overview
Community Relations
Frequently Asked Questions
VIOXX® Information Center
Terms and Conditions of Sales
Corporate News
Executive Speeches
Product News
Research & Development News
Media Contact
Newsroom
Corporate News
Photos
Executive Speeches
Product News
CANCIDAS
®
COSOPT
®
COZAAR
®
CRIXIVAN
®
EMEND
®
FOSAMAX
®
FOSAVANCE
®
GARDASIL
®
INTRON A
®
INVANZ
®
ISENTRESS
®
JANUMET
TM
JANUVIA
®
MAXALT
®
PEGETRON
®
PROPECIA
®
PROSCAR
®
ROTATEQ
®
SINEMET
®
SINGULAIR
®
VARIVAX
®
III
VASOTEC
®
VICTRELIS
TM
VIOXX
®
ZOCOR
®
ZOLINZA
®
ZOSTAVAX
TM
EZETROL
®
Research & Development News
Media Contact
ROTATEQ
®
Press Releases
Jul 21, 2010
NACI Strengthens Recommendations on Rotavirus Vaccination
Jan 21, 2008
National Vaccine Advisory Committee Issues Recommended Use For RotaTeq
®
Aug 23, 2006
RotaTeq™ Is Approved In Canada
May 04, 2006
Canadian Mirage Study Confirms Rotavirus As Severe Gastrointestinal Disease For Infants With Significant Impact On Parents
Jan 05, 2006
Merck's Investigational Rotavirus Vaccine Effectively Protects Infants Against Severe Rotavirus Disease
Product Monograph / Prescribing Information / Product Information
Click here
Studies
Disease Fact Sheets
Aug 23, 2006
Rotavirus Gastroenteritis
Product Fact Sheets
Aug 23, 2006
RotaTeq™ (rotavirus vaccine, live, oral, pentavalent)
Photos
B-Roll
What's New
Gardasil
®
Approved To Help Prevent Anal Cancer In Women And Men
Contact
Media contacts
.
Printer friendly
This site is for residents of Canada. / This site was updated on October 26, 2011.